News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,872 Results
Type
Article (8064)
Company Profile (16)
Press Release (224792)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (64857)
Career Advice (300)
Deals (14964)
Drug Delivery (29)
Drug Development (37634)
Employer Resources (24)
FDA (6500)
Job Trends (5020)
News (124397)
Policy (11847)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
Academia (643)
Accelerated approval (2)
Adcomms (7)
Allergies (35)
Alliances (15280)
ALS (28)
Alzheimer's disease (612)
Antibody-drug conjugate (ADC) (39)
Approvals (6543)
Artificial intelligence (100)
Autoimmune disease (10)
Automation (3)
Bankruptcy (149)
Best Places to Work (4700)
BIOSECURE Act (1)
Biosimilars (20)
Biotechnology (18)
Bladder cancer (45)
Brain cancer (15)
Breast cancer (104)
Cancer (1108)
Cardiovascular disease (68)
Career advice (264)
Career pathing (4)
CAR-T (89)
Cell therapy (215)
Cervical cancer (12)
Clinical research (31632)
Collaboration (300)
Compensation (85)
Complete response letters (7)
COVID-19 (999)
CRISPR (18)
C-suite (81)
Cystic fibrosis (41)
Data (1266)
Denatured (1)
Depression (18)
Diabetes (105)
Diagnostics (2319)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (46)
Drug pricing (42)
Drug shortages (17)
Duchenne muscular dystrophy (39)
Earnings (33554)
Editorial (13)
Employer branding (1)
Employer resources (19)
Events (31462)
Executive appointments (250)
FDA (7138)
Featured Employer (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (270)
Gene editing (46)
Generative AI (10)
Gene therapy (129)
GLP-1 (192)
Government (1356)
Grass and pollen (2)
Guidances (33)
Healthcare (6327)
Huntington's disease (4)
IgA nephropathy (14)
Immunology and inflammation (34)
Indications (15)
Infectious disease (1063)
Inflammatory bowel disease (59)
Inflation Reduction Act (5)
Influenza (25)
Intellectual property (49)
Interviews (45)
IPO (8104)
IRA (18)
Job creations (592)
Job search strategy (227)
Kidney cancer (7)
Labor market (5)
Layoffs (45)
Leadership (3)
Legal (2125)
Liver cancer (39)
Lung cancer (158)
Lymphoma (76)
Machine learning (1)
Management (7)
Manufacturing (98)
MASH (37)
Medical device (4634)
Medtech (4635)
Mergers & acquisitions (7205)
Metabolic disorders (277)
Multiple sclerosis (37)
NASH (8)
Neurodegenerative disease (25)
Neuropsychiatric disorders (4)
Neuroscience (814)
NextGen: Class of 2025 (1531)
Non-profit (744)
Northern California (1242)
Obesity (139)
Opinion (78)
Ovarian cancer (53)
Pain (36)
Pancreatic cancer (50)
Parkinson's disease (67)
Partnered (5)
Patents (129)
Patient recruitment (58)
Peanut (17)
People (15329)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (10135)
Phase II (13952)
Phase III (10448)
Pipeline (721)
Policy (31)
Postmarket research (816)
Preclinical (3697)
Press Release (9)
Prostate cancer (50)
Psychedelics (11)
Radiopharmaceuticals (126)
Rare diseases (163)
Real estate (1066)
Recruiting (7)
Regulatory (9252)
Reports (13)
Research institute (570)
Resumes & cover letters (39)
Rett syndrome (3)
RNA editing (2)
RSV (16)
Schizophrenia (25)
Series A (45)
Series B (31)
Service/supplier (2)
Sickle cell disease (24)
Southern California (1082)
Special edition (2)
Spinal muscular atrophy (35)
Sponsored (14)
Startups (738)
Stomach cancer (5)
Supply chain (23)
Tariffs (1)
The Weekly (1)
United States (10411)
Vaccines (203)
Venture capitalists (5)
Weight loss (76)
Women's health (6)
Worklife (4)
Date
Today (64)
Last 7 days (226)
Last 30 days (1272)
Last 365 days (16134)
2025 (4321)
2024 (17192)
2023 (19364)
2022 (22678)
2021 (24129)
2020 (22256)
2019 (14787)
2018 (10872)
2017 (11750)
2016 (9813)
2015 (12061)
2014 (8362)
2013 (6084)
2012 (6269)
2011 (6973)
2010 (6367)
Location
Africa (189)
Alabama (17)
Alaska (2)
Arizona (54)
Arkansas (3)
Asia (17704)
Australia (4870)
California (2800)
Canada (1097)
China (229)
Colorado (120)
Connecticut (159)
Delaware (56)
Europe (30645)
Florida (439)
Georgia (70)
Idaho (6)
Illinois (201)
India (20)
Indiana (121)
Japan (89)
Kansas (14)
Kentucky (5)
Louisiana (4)
Maine (36)
Maryland (351)
Massachusetts (2005)
Michigan (52)
Minnesota (104)
Missouri (34)
Montana (11)
Nebraska (8)
Nevada (39)
New Hampshire (36)
New Jersey (971)
New Mexico (3)
New York (893)
North Carolina (389)
North Dakota (2)
Northern California (1242)
Ohio (65)
Oklahoma (1)
Oregon (8)
Pennsylvania (652)
Puerto Rico (7)
Rhode Island (7)
South America (312)
South Carolina (9)
Southern California (1082)
Tennessee (40)
Texas (416)
Utah (68)
Virginia (76)
Washington D.C. (17)
Washington State (340)
West Virginia (2)
Wisconsin (12)
232,872 Results for "oxford immunotec limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem
April 14, 2025
·
3 min read
Press Releases
Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions
April 9, 2025
·
4 min read
Press Releases
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
March 19, 2025
·
3 min read
Press Releases
Top Neuroscientist Matthew Anderson Appointed Co-Director of the Oxford-Harrington Rare Disease Centre
February 19, 2025
·
3 min read
FDA
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection.
September 22, 2022
·
3 min read
Press Releases
Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps
February 5, 2025
·
5 min read
Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine
Oxford Nanopore Technologies announced the launch of a new Pharmacogenomics Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing target enrichment technology with Oxford Nanopore’s sequencing platform.
May 22, 2024
·
3 min read
Business
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
Azenta, Inc. announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.
May 13, 2024
·
3 min read
Genetown
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, announced a sponsored research agreement with The University of Oxford for the development of a vaccine against Epstein-Barr virus.
May 23, 2024
·
4 min read
1 of 23,288
Next
